
The Readout
Your guide to what’s new in biotech. Sign up for the newsletter here.
Most Read


Sage’s debatable data, Hahn’s retort, & biotech’s mixed record in June

CRISPR for cancer, Biogen’s $800m flyer, & Hahn’s VC future

FDA conspiracy theories, closing the Covid vaccine gap, & how to value a Vant

CureVac’s any-day-now data, more FDA conservatism, & a lawsuit about coupons

Pfizer’s 95% vaccine efficacy, disappointment in ALS, & FDA promises of transparency

Trump’s drug EO, a $1 billion Biogen deal, & the case for inaccuracy
